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Dr Y. Joseph Woo (Philadelphia, Pa). That was very nice talk.
Do the valve leaflets move in your model?
Dr McKellar. In this model, they do not. We have verified that
under fluoroscopy, and a main reason that we chose this model
rather than an intracardiac model is because at 30 days it was
much more robust in thrombus formation.
Dr Woo. So have you not created a model system that is exag-
gerating the thrombus generation? Isn’t the relative amount of de-
crease in thrombus formation in your experimental group always
going to look better because your control group is so bad? Most
valves in human beings when placed into a native position would
not generate that much clot.
Dr McKellar. Correct, and that is why we choose this valve.
When we were developing this model, one of our first studies
was to compare this with an orthotopic mitral valve position with-
out any anticoagulation, and we found a lot less thrombus in the
orthotopic position. We therefore chose the heterotopic position,
because the pig grows so rapidly and at 30 days we can keep the
pig at minimum growth. So in a short time we can develop a lot
of thrombus. I do accept the criticism that this may not completely
represent reality of the mechanical valve.
Dr Woo. I just think that it limits the conclusions that you can
draw.
Dr McKellar. Thank you for your question.
DrMichael E. Jessen (Dallas, Texas). I enjoyed your talk, and I
really hope that this works out, because I think there is potential in
this for patients. One of the difficulties I have with this, though, is
that you measured the intensity of anticoagulation in the 2 treat-
ment groups by different methods. One was by anti–factor Xa ac-
tivity and one was by partial thromboplastin time. So because you
were not using exactly the same targets, is it possible that the dif-
ference just represents an intensity of anticoagulation, a higher
dose of anticoagulation if you like, in one group, and not so
much an effect specific to the drug itself?1416 The Journal of Thoracic and Cardiovascular SurDr McKellar. It could, and thank you for your question. This
is in large part why we wanted to do a more global evaluation of
clot function or clot strength with thromboelastography. Accord-
ing to what is out there in the literature, the anti-Xa levels are
fairly well established for the low–molecular weight heparins,
whereas for the dabigatran etexilate group it is a little less clear.
The best evidence out there for readily available tests for direct
thrombin inhibitors is an APPT of 2 to 2.5 times normal, but I
understand what you are saying. And we thought that we would
see perhaps something like that in the thromboelastographic
data, but in fact we saw the reverse. We saw what appears in vi-
tro to be preserved clot function by thromboelastography with
dabigatran etexilate versus enoxaparin. As for the anti-Xa level
of 0.6, were we overly anticoagulating in either arm? What we
saw on valve thrombus was different from what we saw on
thromboelastography, leaving the question open. A good ques-
tion. Thank you.
Dr Carlos J. Troconis (Santiago, Dominican Republic). There
have been several studies in Europe and South Africa about se-
lected cases of On-X valves in aortic replacement without the
use of warfarin anticoagulation, treating them only with antiplate-
let therapy to avoid thromboembolic events. Do you have any com-
ments about this?
Dr McKellar.We have used this model to look at dual antipla-
telet therapy with aspirin and clopidogrel. I know that others
around the world have published results of that in human beings.
I think that the best place to study that is in patients with good
left ventricular function and high flow across a mechanical aortic
valve. I know that the On-X people are kind of leading the way in
doing some of those trials. But havewe done that in human beings?
If that is your question, no, we haven’t. I do hope that our and other
data would push the community toward clinical trials to try this
agent in human beings.
Dr Glen Van Arsdell (Toronto, Ontario, Canada). Pigs are no-
toriously hard to anticoagulate. With unfractionated heparin, you
have to give enormous doses. I have 2 questions in that regard.
One is the timing of measuring your anti-Xa values. Are you really
satisfied that the low–molecular weight heparin was anticoagulat-
ing the whole time? The second thing is, if you look at the data on
mechanical valves in pregnancy (a hypercoagulable state), low–
molecular weight heparin is not as effective as you would like it
to be in terms of preventing valve thrombosis. Does low–molecu-
lar weight heparin really anticoagulate well enough in the face of
a potentially hypercoagulable physiology?
Dr McKellar. Thank you for your question. According to the
American College of Chest Physicians guidelines for deep vein
thrombosis and pulmonary embolism prophylaxis or treatment,
the best data they have is an anti-Xa of 0.6 at 4 hours after admin-
istration, and that is what we duplicated in this study. As towhether
there are subtle nuances between the species, granted, I don’t have
that perfect answer.
Dr. Van Arsdell. So you didn’t measure anti-Xa levels right be-
fore giving your second dose?
DrMcKellar. Before we did any of the valve implantations, we
did a dosing study to find the exact right dose of dabigatran etex-
ilate for our species, as well as the correct dose of enoxaparin, and
we did several different doses. The dose we chose consistently
yielded a value of 0.6 at 4 hours.gery c June 2011
